Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2021)	11/6/2007 12:13:27 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SNTS seems to have found support at the $2 level since it dropped from the $5.25 level in August. bigcharts.marketwatch.com SNTS has been trimming its loss for 4 consecutive Qs & revenues have significantly increased (in triple digit improvements) also for 4Qs. Zegerid prescriptions reportedly grew approximately 12% in the 3rdQ compared with the 2ndQ, while the delayed released brands, Nexium, Prevacid, Protonix, and Aciphex, as a group had negative growth of more than 2%.For the 9Ms ended September 30, prescription for Zegerid grew approximately 143% in contrast to 2% negative growth for prescriptions for the delayed release brand. In August was when Par alleged that U.S. Patents for ZEGERID are invalid, unenforceable and/or will not be infringed by Par's manufacture, use, or sale of the product for which it had submitted an ANDA.<g> At any rate, SNTS shares are up > 7% today & it seems they could get back to the $4 level some time in the near future.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2021)	3/18/2008 3:41:11 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

Well, Besides Insert Therapeutics, & Calando Pharmaceuticals, ARWR is going to have another B&P subsidiary.<g> The stock is up 9.96% on moderate volume of 183,468 still < its ADV. bigcharts.marketwatch.com ARWR announced today the formation of a spin-off company, Ensysce Biosciences, that will focus on research into the medical therapeutic applications of carbon nanotubes. Its Unidym subsidiary has licensed its extensive nanotechnology patent portfolio to Ensysce & in return holds a significant equity position in Ensysce. Ensysce stems from the research of the late Dr. Richard Smalley, the 1996 Nobel Laureate for Chemistry from Rice University, who was among the pioneers in considering the potential therapeutic applications for carbon nanotubes. Ensysce will be working with several of the world’s leading chemists and clinicians in the field developing carbon nanotube based therapeutics. One of its first moves is to fund the existing studies using carbon nanotubes for delivery of siRNA using animal models, led by Dr. Bruce Weisman at Rice University and Dr. Garth Powis at the University of Texas M. D. Anderson Cancer Center. Ensysce will fund the research at Stanford being led by Dr. Hongjie Dai and focused on the delivery of chemotherapy drugs such as taxol and doxorubicin using carbon nanotubes. Ensysce is also looking at ways of using carbon nanotubes to directly treat tumor cells.It will also fund a team led by Dr. Lon Wilson of Rice & Dr. Steven Curley of the M. D. Anderson to move into human trials a cancer therapy that uses carbon nanotubes exposed during treatment to RF radiation. Unidym will provide contract services to Ensysce, including supplies of research grade nanotubes, back-office & accounting support. Initial operating costs are funded by an angel investor interested in the therapeutic applications of carbon nanotubes. In spite of its spike in Dec., ARWR still isn't off from the DT coming from its Jun H at $7.69 (That was below its all time H on May 2006 H at $7.76 which was above its initial Sep 2004 H at $7.15 <g>) bigcharts.marketwatch.com Bernard